Corrigendum to “Administration of low molecular weight and unfractionated heparin during percutaneous coronary intervention” [Indian Heart J. 68 (2) (2016) 213–224]
نویسندگان
چکیده
In the article titled “Administration of low molecular weight and unfractionated heparin during percutaneous coronary intervention.” [1], the name of the first author was given incorrectly as Sadegh Ali-Hassan-Sayegh. The author's name should have been written as Sadeq Ali-Hasan-Al-Saegh. The revised authors' list is shown above. These two spelling are belonging to an author. The authors would like to apologise for any inconvenience caused.
منابع مشابه
Anticoagulants in heart disease: current status and perspectives.
List of abbreviations . . . . . . . . . . . . . . . . . . 2 Preamble: purposes and scope of the task force . . 2 Blood coagulation . . . . . . . . . . . . . . . . . . . . 3 Haemostasis . . . . . . . . . . . . . . . . . . . . . 3 Arterial thrombosis . . . . . . . . . . . . . . . . . 3 Tissue factor . . . . . . . . . . . . . . . . . . . . . 3 Tissue factor pathway inhibitor . . . . . . . . . . 3 ...
متن کاملSubstitution of fractionated for unfractionated heparin during high-risk percutaneous coronary intervention: has the problem been solved?
i t n ercutaneous coronary intervention (PCI) is frequently erformed in patients who received fibrinolytic therapy for cute myocardial infarction (MI). Currently, unfractionated eparin is the most commonly used antithrombin therapy in his situation. However, unfractionated heparin has certain imitations. It has a narrow therapeutic range, monitoring of he activated clotting time is required, an...
متن کاملParenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease.
Anticoagulants are a mainstay of cardiovascular therapy, and parenteral anticoagulants have widespread use in cardiology, especially in acute situations. Parenteral anticoagulants include unfractionated heparin, low-molecular-weight heparins, the synthetic pentasaccharides fondaparinux, idraparinux and idrabiotaparinux, and parenteral direct thrombin inhibitors. The several shortcomings of unfr...
متن کاملChanging roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention.
I n the development of percutaneous intervention, Dotter first used unfractionated heparin (UFH) alone when performing peripheral angioplasty. In the 1970s Gruentzig added 1 g of aspirin (ASA) for three days in coronary angioplasty, which was started the day before the procedure. Over the ensuing years empiric attempts were made to improve patient outcomes using dextran and dipyridamole but wit...
متن کاملEvaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial.
BACKGROUND Factor Xa and factor IIa (thrombin) play roles in thrombotic complications after percutaneous coronary intervention. M118 is a novel low-molecular-weight heparin that has been rationally designed to capture the desired attributes of unfractionated heparin (UFH) and low-molecular-weight heparin: Potent activity against factor Xa and IIa, predictable pharmacokinetics after both intrave...
متن کامل